Stay updated on Ipilimumab/Nivolumab Combo in Rare Cancers Clinical Trial

Sign up to get notified when there's something new on the Ipilimumab/Nivolumab Combo in Rare Cancers Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Ipilimumab/Nivolumab Combo in Rare Cancers Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    The site revision identifier changed from v3.7.2 to v3.8.0, while the study page still displays a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-01T04:12:03.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    A site-wide notice announces NIH’s transition and says agencies are using “Super Intelligence” in place of “Artificial Intelligence.”
    Difference
    1%
    Check dated 2026-10-25T04:42:29.000Z thumbnail image
  3. Check
    17 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov page remains a 403 Forbidden error, with its footer revision identifier updated from v3.7.1 to v3.7.2.
    Difference
    0.2%
    Check dated 2026-10-18T04:45:20.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    The footer’s site revision indicator changed from v3.7.0 to v3.7.1 on the 403 error page.
    Difference
    0.2%
    Check dated 2026-10-11T08:20:54.000Z thumbnail image
  5. Check
    45 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error with the site header, replacing the usual study record content with a notice.
    Difference
    18%
    Check dated 2026-09-20T03:15:15.000Z thumbnail image
  6. Check
    66 days ago
    Change Detected
    Summary
    The page revision was updated from v3.6.5 to v3.6.6, representing a small update to the study page.
    Difference
    0.1%
    Check dated 2026-08-29T23:35:44.000Z thumbnail image

Stay in the know with updates to Ipilimumab/Nivolumab Combo in Rare Cancers Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Ipilimumab/Nivolumab Combo in Rare Cancers Clinical Trial page.